medigraphic.com

2019, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2019; 57 (5)

Acetylsalicylic acid in prevention of pre-eclampsia

Godínez V, Godínez-Vázquez VJ, Godínez-Vázquez PR, Sosa-Bustamante GP, Díaz de León-Morales LV

Language: Spanish
References: 30
Page: 270-276
PDF size: 129.68 Kb.


ABSTRACT

Background: Pre-eclampsia (PE) is an important cause of morbidity and mortality in our country.
Objective: Evaluate if the administration of acetylsalicylic acid (ASA) at a low dose reduces its presence.
Methods: Comparative, cohort study. Pregnant women with risk factors for PE: Primigravidae, PE antecedent and twin pregnancy were included. Primigravidae and multigested with previous vascular pathology weren’t included. Group 1: 150, 11 excluded, 80 mg ASA from week 20 at the end of pregnancy. Group II: 150, without ASA. The presence of PE or gestational hypertension (HG) was monitored. General data and clinical controls were taken. Chi square and relative risk (RR) were calculated.
Results: Group I: n = 139, 26 ± 5.6 years, 9% PE. Group II: n = 150, 25.5 ± 5.6 years, PE 20% (p = 0.01), RR 0.47 (95% CI 0.19 - 0.87) (p = 0.01), attributable risk -0.11 equivalent to an absolute reduction of 11% for PE in group I.
Conclusions: Pregnant women with risk factor for PE who received ASA diminished the risk of developing PE in 50%.


REFERENCES

  1. Organización Mundial de la Salud. Prevención y tratamiento de la preeclampsia y la eclampsia. Ginebra, Suiza: OMS; 2011. Disponible en: http://www.who.int/reproductivehealth/publications/mate rnal_perinatal_health/rhr_11_30/es/.

  2. Mone F, Mulcahy C, McParland P, McAuliffe FM. Should we recommend universal aspirin for all pregnant women? Am J Obstet Gynecol. 2016;(2):141.e1-141.e5. DOI: 10.1016/j.ajog.2016.09.086.

  3. Mol BW, Roberts CT, Thangaratinam S, Magee LA, de Groot CJ, Hofmeyr GJ. Pre-eclampsia. Lancet. 2016; 387(10022):999-1011.

  4. Organización Mundial de la Salud. Mortalidad materna. Ginebra, Suiza: OMS; 2018. Disponible en: http://www. who.int/mediacentre/factsheets/fs348/es/

  5. Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985;1(8433):840-2.

  6. Benigni A, Gregorini G, Frusca T, Chiabrando C, Ballerini S, Valcamonico A, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med. 1989; 321(6):357-62.

  7. Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensinsensitiveprimigravidae. Lancet. 1986;1(8471):1-3.

  8. Schröcksnadel H, Sitte B, Alge A, Steckel-Berger G, Schwegel P, Pastner E, et al. Low-dose aspirin in primigravidae with positive roll-over test. Gynecol Obstet Invest. 1992;34(3):146-50.

  9. Dixon CL, Marrs C, Costantine MM, Pacheco LD, Saade GR, Chiossi G. Effect of Low-Dose Aspirin on the Time of Onset of Preeclampsia and Time of Delivery. Am J Perinatol. 2017;34(12):1219-1226. DOI: 10.1055/s-0037-1602421.

  10. Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for Prevention of Preeclampsia. Drugs. 2017;77(17):1819-1831. DOI: 10.1007/s40265-017-0823-0.

  11. Imperiale TF, Petrulis AS. A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA. 1991;266(2):260-4.

  12. Lan PG, Gillin AG, Pelosi M, Tooher J, Sandager P, Hyett J. Effect of early use of low-dose aspirin therapy on late-onset preeclampsia. J Matern Fetal Neonatal Med. 2019;32(13):2137-2142. DOI: 10.1080/14767058. 2018.1427718.

  13. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. Lancet. 1993;341(8842): 396-400.

  14. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994;343(8898):619-29.

  15. Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, et al. Prevention of preeclampsia with lowdose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1993;329(17):1213-8.

  16. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338(11):701-5.

  17. Golding J. A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. Br J Obstet Gynaecol. 1998;105(3):293-9.

  18. Sibai BM. Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol. 1998;179(5):1275-8.

  19. Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B, et al. Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol. 1998;105(3):286-92.

  20. Roberge S, Odibo A, Bujold E. Aspirin for the Prevention of Preeclampsia and Intrauterine Growth Restriction. Clin Lab Med. 2016;36(2):319-29. DOI: 10.1016/j.cll.2016.01.013

  21. Campos A. The Role of Aspirin in Preeclampsia Prevention: State of the Art. Acta Med Port. 2015;28(4): 517-24.

  22. Panagodage S, Yong HE, Da Silva F, Borg AJ, Kalionis B, Brennecke SP, et al. Low-Dose Acetylsalicylic Acid Treatment Modulates the Production of Cytokines and Improves Trophoblast Function in an in Vitro Model of Early-Onset Preeclampsia. Am J Pathol. 2016;186(12): 3217-3224. DOI: 10.1016/j.ajpath.2016.08.010.

  23. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5): 1122-31. DOI: 10.1097/01.AOG.0000437382.03963. 88.

  24. Centro Nacional de Excelencia Tecnológica en Salud. Guía de Práctica Clínica (GPC) para la Detección y Diagnóstico de Enfermedades Hipertensivas del Embarazo. México: Secretaría de Salud; 2010. Disponible en: http://www. cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/ 058_GPC_Enf.HipertdelEmb/HIPERTENSION_EMBARAZ ADAS_EVR_CENETEC.pdf

  25. Instituto Mexicano del Seguro Social .Guía de Práctica Clínica (GP) Prevención, Diagnóstico y Tratamiento de la Preeclampsia en Segundo y Tercer Nivel de Atención. Ciudad de México, México: IMSS; 2017. Disponible en: http://www.imss.gob.mx/sites/all/statics/guiasclinicas/020 GER.pdf

  26. Yao S, Wu H, Yu Y. [Early intervention with aspirin for preventing preeclampsia in high-risk women: a metaanalysis]. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35(6): 868-73.

  27. Allhouse AA, Jessel RH, Heyborne KD. The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. J Perinatol. 2016;36(6):427- 31.

  28. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, Group PC. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791-1798.

  29. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003;101(6):1319-1332.

  30. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Int Med. 2014;160(10):695-703.




2020     |     www.medigraphic.com